CLINICAL TRIALS PROFILE FOR ZOLMITRIPTAN
✉ Email this page to a colleague
All Clinical Trials for Zolmitriptan
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00382993 ↗ | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) | Completed | GlaxoSmithKline | Phase 3 | 2006-12-01 | This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2] |
| NCT00383162 ↗ | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) | Completed | GlaxoSmithKline | Phase 3 | 2006-11-01 | This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 1 of 2] |
| NCT00617695 ↗ | Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents | Completed | AstraZeneca | Phase 3 | 2003-09-01 | The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches |
| NCT00617747 ↗ | Efficacy and Tolerability of Zolmitriptan Nasal Spray | Completed | AstraZeneca | Phase 3 | 2002-09-01 | The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches |
| NCT00637286 ↗ | ZAP, US. Zomig for Appropriate for Primary Care | Completed | AstraZeneca | Phase 4 | 2004-07-01 | The purpose of this study is to determine how useful and effective the use of ZOMIG-ZMT™ (zolmitriptan) 5.0 mg and ZOMIG® Nasal Spray (zolmitriptan) 5.0 mg is for patients, in treating migraine over a period of 6 months |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Zolmitriptan
Condition Name
Clinical Trial Locations for Zolmitriptan
Trials by Country
Clinical Trial Progress for Zolmitriptan
Clinical Trial Phase
Clinical Trial Sponsors for Zolmitriptan
Sponsor Name
